Rigel's Q3 Net Income Soars 125% on Strong Product Sales

TL;DR

**RIGL is finally printing cash, with net income up 125% this quarter, making it a strong buy as product sales explode.**

AI Summary

Rigel Pharmaceuticals Inc. reported a significant increase in net income to $27.9 million for the three months ended September 30, 2025, up from $12.4 million in the same period of 2024, representing a 124.6% increase. For the nine months ended September 30, 2025, net income surged to $98.9 million, a substantial rise from $3.1 million in the prior year. Total revenues for the quarter increased by 25.6% to $69.5 million, driven primarily by a 64.6% increase in net product sales to $64.1 million, compared to $38.9 million in Q3 2024. Collaboration revenues, however, decreased to $5.4 million from $16.4 million in Q3 2024. The company's total assets grew to $242.5 million as of September 30, 2025, from $164.0 million at December 31, 2024, largely due to an increase in short-term investments to $88.6 million from $20.6 million. Cash and cash equivalents decreased to $48.5 million from $56.7 million. Strategic outlook includes continued commercialization of TAVALISSE, REZLIDHIA, and GAVRETO, with GAVRETO commercialization beginning in June 2024. Risks include reliance on product sales and collaboration agreements, as well as the inherent uncertainties of clinical development for R289 and other pipeline programs.

Why It Matters

Rigel's impressive Q3 performance, driven by a 64.6% jump in product sales, signals a strong commercial trajectory for its approved therapies, particularly with the recent addition of GAVRETO. This financial health provides investors with increased confidence in the company's ability to fund ongoing R&D, potentially leading to new treatments and sustained growth. For employees, robust sales and profitability secure jobs and may lead to further investment in talent and infrastructure. Customers benefit from continued access to critical therapies like TAVALISSE, REZLIDHIA, and GAVRETO, while the broader market sees a strengthening player in the competitive biotechnology landscape, potentially spurring innovation.

Risk Assessment

Risk Level: medium — While Rigel reported strong net income and product sales growth, its cash and cash equivalents decreased by $8.2 million during the nine months ended September 30, 2025, to $48.5 million. The company also has significant current liabilities of $94.4 million, including $29.8 million in current loans payable, which could pose liquidity challenges despite the overall increase in total assets.

Analyst Insight

Investors should consider increasing their position in RIGL, given the substantial growth in net income and product sales, particularly with the recent commercialization of GAVRETO. Monitor the company's cash flow and debt management closely, but the current trajectory suggests a positive outlook for revenue generation and profitability.

Financial Highlights

revenue

$69.5M

operating Margin

40.9%

total Assets

$242.5M

total Debt

$59.7M

net Income

$27.9M

cash Position

$48.5M

revenue Growth

+25.6%

Revenue Breakdown

Key Numbers

• $27.9M — Net Income (Q3 2025) (Increased 124.6% from $12.4M in Q3 2024)
• $98.9M — Net Income (YTD Sept 2025) (Significantly up from $3.1M in YTD Sept 2024)
• $64.1M — Product Sales, Net (Q3 2025) (Increased 64.6% from $38.9M in Q3 2024)
• $166.6M — Product Sales, Net (YTD Sept 2025) (Increased from $98.4M in YTD Sept 2024)
• $69.5M — Total Revenues (Q3 2025) (Increased 25.6% from $55.3M in Q3 2024)
• $224.5M — Total Revenues (YTD Sept 2025) (Increased from $121.7M in YTD Sept 2024)
• $48.5M — Cash and Cash Equivalents (Sept 30, 2025) (Decreased from $56.7M at Dec 31, 2024)
• $88.6M — Short-term Investments (Sept 30, 2025) (Increased from $20.6M at Dec 31, 2024)
• $117.6M — Total Stockholders' Equity (Sept 30, 2025) (Increased significantly from $3.3M at Dec 31, 2024)
• $94.4M — Total Current Liabilities (Sept 30, 2025) (Increased from $63.3M at Dec 31, 2024)

Key Players & Entities

• RIGEL PHARMACEUTICALS INC (company) — registrant
• TAVALISSE (company) — FDA-approved product
• REZLIDHIA (company) — FDA-approved product
• GAVRETO (company) — FDA-approved product
• FDA (regulator) — US Food and Drug Administration
• Blueprint Medicines Corporation (company) — seller of GAVRETO rights
• Novo Nordisk (company) — Forma Therapeutics, Inc. acquired by
• Eli Lilly and Company (company) — collaboration partner for RIPK1 inhibitor program
• $27.9 million (dollar_amount) — Net income for Q3 2025
• $98.9 million (dollar_amount) — Net income for nine months ended Sept 30, 2025

FAQ

Risk Factors

• Reliance on Product Sales and Collaboration Agreements [high — financial]: The company's financial performance is significantly dependent on the success of its marketed products (TAVALISSE, REZLIDHIA, GAVRETO) and its ability to secure and maintain collaboration agreements. A decline in product sales or loss of key partnerships could materially impact revenue and profitability.
• Clinical Development Uncertainties [high — operational]: The success of pipeline programs, such as R289, is subject to inherent uncertainties in clinical development, including regulatory approvals and market acceptance. Delays or failures in these programs represent a significant risk to future growth.
• Increased Short-Term Investments [medium — financial]: Short-term investments increased substantially from $20.6 million at December 31, 2024, to $88.6 million as of September 30, 2025. While this can provide liquidity, it also represents a strategic allocation of capital that could be used for other growth initiatives.
• Increased Current Liabilities [medium — financial]: Total current liabilities rose to $94.4 million from $63.3 million at year-end 2024. This increase, particularly in loans payable and acquisition-related liabilities, warrants monitoring for potential short-term financial strain.
• Regulatory Approval and Compliance [high — regulatory]: The pharmaceutical industry is heavily regulated. Rigel faces risks related to obtaining and maintaining regulatory approvals for its products and ensuring ongoing compliance with stringent healthcare regulations.

Industry Context

The pharmaceutical industry is characterized by high R&D costs, long development cycles, and stringent regulatory oversight. Companies like Rigel compete based on innovation, clinical trial success, and effective commercialization strategies. The market for oncology and autoimmune disease treatments, where Rigel focuses, is highly competitive and dynamic.

Regulatory Implications

Rigel's operations are subject to extensive regulation by bodies like the FDA. Successful commercialization and continued growth depend on maintaining regulatory compliance, obtaining approvals for new indications or products, and navigating evolving healthcare policies.

What Investors Should Do

1. Monitor collaboration revenue trends
2. Analyze R&D pipeline progress
3. Evaluate debt repayment strategy
4. Assess the sustainability of net income growth

Key Dates

• 2024-06-01: GAVRETO commercialization began — Marks the launch of a key product, contributing to future revenue growth.
• 2025-09-30: End of Q3 2025 — Reporting period for the significant increase in net income and product sales.
• 2024-12-31: End of Fiscal Year 2024 — Baseline for comparison of asset and liability changes.

Glossary

Accumulated deficit

The total net losses of a company since its inception, minus any net gains. It represents a negative retained earnings balance. (Rigel has a significant accumulated deficit of $1.29 billion, indicating historical unprofitability, though recent performance shows a strong turnaround.)

Revenue reserves and refund liability

Represents amounts set aside for potential product returns, rebates, or chargebacks, which are common in the pharmaceutical industry. (A liability of $30.0 million indicates potential future outflows related to sales, impacting net revenue recognition.)

Contract revenues from collaborations

Revenue generated from agreements with other companies, often involving licensing, research, or co-development of pharmaceutical products. (This revenue stream decreased significantly, highlighting a shift in the company's revenue composition towards product sales.)

Short-term investments

Investments that are expected to be converted into cash within one year. (A substantial increase to $88.6 million suggests a strategic deployment of capital, potentially from recent financing or improved cash flow.)

Year-Over-Year Comparison

Rigel Pharmaceuticals Inc. has demonstrated a significant improvement in financial performance compared to the prior year. Total revenues for the nine months ended September 30, 2025, more than doubled to $224.5 million from $121.7 million in the same period of 2024, driven by a substantial 67.3% increase in net product sales. Net income has seen a dramatic turnaround, surging to $98.9 million year-to-date from a mere $3.1 million, indicating improved profitability. While cash and cash equivalents have slightly decreased, total assets have grown considerably, largely due to a significant increase in short-term investments, and total stockholders' equity has expanded substantially from a deficit position.

Key Financial Figures

• $0.001 — h registered: Common Stock, par value $0.001 per share RIGL The Nasdaq Stock Mar

Filing Documents

• rigl-20250930x10q.htm (10-Q) — 2533KB
• rigl-20250930xex10d2.htm (EX-10.2) — 27KB
• rigl-20250930xex10d3.htm (EX-10.3) — 42KB
• rigl-20250930xex31d1.htm (EX-31.1) — 15KB
• rigl-20250930xex31d2.htm (EX-31.2) — 16KB
• rigl-20250930xex32d1.htm (EX-32.1) — 9KB
• rigl-20250930x10q005.jpg (GRAPHIC) — 81KB
• rigl-20250930xex10d2001.jpg (GRAPHIC) — 12KB
• 0001104659-25-106268.txt ( ) — 9802KB
• rigl-20250930.xsd (EX-101.SCH) — 58KB
• rigl-20250930_cal.xml (EX-101.CAL) — 62KB
• rigl-20250930_def.xml (EX-101.DEF) — 222KB
• rigl-20250930_lab.xml (EX-101.LAB) — 491KB
• rigl-20250930_pre.xml (EX-101.PRE) — 362KB
• rigl-20250930x10q_htm.xml (XML) — 1777KB

Financial Statements

Financial Statements 3 Condensed Balance Sheets — September 30, 2025 (Unaudited) and December 31, 2024 3 Condensed Statements of Operations (Unaudited) — three and nine months ended September 30, 2025 and 2024 4 Condensed Statements of Comprehensive Income (Unaudited) — three and nine months ended September 30, 2025 and 2024 5 Condensed Statements of Stockholders' Equity (Deficit) (Unaudited) — three and nine months ended September 30, 2025 and 2024 6 Condensed Statements of Cash Flows (Unaudited) — nine months ended September 30, 2025 and 2024 7 Notes to Condensed Financial Statements (Unaudited) 8 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 26 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 48 Item 4.

Controls and Procedures

Controls and Procedures 48 PART II OTHER INFORMATION 48 Item 1.

Legal Proceedings

Legal Proceedings 48 Item 1A.

Risk Factors

Risk Factors 49 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 102 Item 3. Defaults Upon Senior Securities 102 Item 4. Mine Safety Disclosures 102 Item 5. Other Information 102 Item 6. Exhibits 103

Signatures

Signatures 104 2 Table of Contents

FINANCIAL INFORMATIO N

PART I. FINANCIAL INFORMATIO N

Financial Statements

Item 1. Financial Statements RIGEL PHARMACEUTICALS, INC. CONDENSED BALANCE SHEET S (In thousands) As of September 30, 2025 December 31, 2024 (1) (unaudited) Assets Current assets: Cash and cash equivalents $ 48,534 $ 56,746 Short-term investments 88,609 20,575 Accounts receivable, net 45,925 41,615 Inventories 13,303 6,002 Prepaid and other current assets 18,556 10,165 Total current assets 214,927 135,103 Property and equipment, net 54 92 Intangible assets, net 25,336 27,100 Operating lease right-of-use assets 1,050 246 Other assets 1,167 1,435 Total assets $ 242,534 $ 163,976 Liabilities and stockholders' equity Current liabilities: Accounts payable $ 3,846 $ 3,339 Accrued compensation 10,065 10,139 Accrued research and development 4,816 4,073 Acquisition-related liabilities 5,000 — Revenue reserves and refund liability 30,020 26,440 Loans payable, net, current portion 29,761 7,272 Other accrued liabilities 8,943 10,396 Deferred revenue 1,355 1,355 Lease liabilities, current portion 594 285 Total current liabilities 94,400 63,299 Acquisition-related liabilities — 5,000 Long-term portion of lease liabilities 556 — Long-term portion of loans payable, net 29,969 52,408 Other long-term liabilities — 39,981 Total liabilities 124,925 160,688 Commitments Stockholders' equity: Common stock 18 18 Additional paid-in capital 1,408,601 1,393,325 Accumulated other comprehensive income 96 10 Accumulated deficit ( 1,291,106 ) ( 1,390,065 ) Total stockholders' equity 117,609 3,288 Total liabilities and stockholders' equity $ 242,534 $ 163,976 (1) The balance sheet as of December 31, 2024 has been derived from the audited financial statements included in Rigel's Annual Report on Form 10-K for the year ended December 31, 2024 filed with the Securities and Exchange Commission (SEC) on March 4, 202 5.

View Full Filing

View this 10-Q filing on SEC EDGAR